Audit of the Effect of Changing From IV to SC Administration of ESA's in Haemodialysis Patients

This study has been completed.
Information provided by:
Sir Charles Gairdner Hospital Identifier:
First received: September 27, 2006
Last updated: May 22, 2008
Last verified: May 2008

The purpose of this study is to audit the effects of changing all hemodialysis patients from intravenous to subcutaneous administration of ESA's, to ensure that a cost-saving is achieved and that this does not occur at the expense of anemia control. The dose changes will occur according to usual clinical care of patients and not along a protocol.

Condition Intervention
Kidney Failure, Chronic
Drug: Eprex; Neorecormon; Aranesp

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Audit of the Effect of Changing From IV to SC Administration of Erythropoiesis Stimulating Agents in Haemodialysis Patients - Real Life Clinical Experience

Resource links provided by NLM:

Further study details as provided by Sir Charles Gairdner Hospital:

Estimated Enrollment: 150
Study Start Date: September 2006
Study Completion Date: April 2008
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
  Show Detailed Description


Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • On haemodialysis at a Sir Charles Gairdner Hospital Unit
  Contacts and Locations
Please refer to this study by its identifier: NCT00382044

Australia, Western Australia
Sir Charles Gairdner Hospital
Perth, Western Australia, Australia, 6009
Sponsors and Collaborators
Sir Charles Gairdner Hospital
Study Director: Neil C Boudville, MBBS Sir Charles Gairdner Hospital
  More Information

No publications provided

Responsible Party: Dr Neil Boudville, Sir Charles Gairdner Hospital Identifier: NCT00382044     History of Changes
Other Study ID Numbers: NB-06-10
Study First Received: September 27, 2006
Last Updated: May 22, 2008
Health Authority: Australia: Human Research Ethics Committee

Keywords provided by Sir Charles Gairdner Hospital:
Kidney Failure, Chronic

Additional relevant MeSH terms:
Kidney Failure, Chronic
Renal Insufficiency
Hematologic Diseases
Renal Insufficiency, Chronic
Kidney Diseases
Urologic Diseases
Darbepoetin alfa
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions processed this record on April 21, 2014